Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 1,003.6% in August

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 215,200 shares, a growth of 1,003.6% from the August 15th total of 19,500 shares. Based on an average daily volume of 214,600 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.8% of the company’s stock are short sold.

Chemomab Therapeutics Stock Down 1.5 %

Chemomab Therapeutics stock traded down $0.03 during midday trading on Thursday, reaching $2.00. 865,881 shares of the stock traded hands, compared to its average volume of 196,616. The stock’s fifty day moving average is $1.36 and its 200-day moving average is $1.02. Chemomab Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.55. The stock has a market cap of $22.10 million, a P/E ratio of -1.38 and a beta of 0.52.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same quarter last year, the firm posted ($0.72) earnings per share. On average, equities analysts predict that Chemomab Therapeutics will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Maxim Group upgraded Chemomab Therapeutics to a “strong-buy” rating in a research report on Friday, May 24th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).